asco@alo33:161708 JSONTXT

Background: The role of regional lymphadenectomy LA in omen ith stage I endometrial carcinoma EC is controversial. The objective of the study is to determine the prognostic impact of LA on survival endpoints of omen ith stage I EC solely of endometrioid histology using match-pair analysis. Survival endpoints included recurrence-free RFS , disease-specific DSS and overall survival OS . Methods: We identified 1257 patients ith stage I EC ho underent hysterectomy beteen 11990 and 62015. Of those, 822 omen underent LA as part of their surgical staging hile 435 did not NLA . 435 omen ith NLA ere matched to 435 omen ho had LA 1:1 match based on 2009 FIGO stage, tumor grade and adjuvant management received observation, vaginal brachytherapy or pelvic external beam radiation treatment . Univariate and multivariate modeling ith Cox regression analysis as carried out for predictors of survival endpoints. Results: Median follo-up time for the study cohort as 48 months. The to groups ere ell balanced except for more peritoneal cytology performed and more loer uterine segment LUS involvement for LA group p= 0.001 for both . 5-year survival endpoints beteen the to groups ere similar. 5-year RFS for omen in the LA group as 93.7 percent vs. 90 percent for NLA group p= 0.081 . Similarly, 5-year DSS as 97.7 percent vs. 98 percent p= 0.536 and 5-year OS as 87.2 percent vs. 91.7 percent p= 0.357 . On multivariate analysis for the entire study cohort, older age, deep myometrial invasion and higher tumor grade ere predictors of orse RFS p= 0.031, p= 0.004 and plt 0.001 , respectively. For DSS, higher tumor grade plt 0.001 , LUS involvement p= 0.028 and FIGO stage IB p= 0.022 ere significant predictors of orse outcome. For OS, older age and LUS involvement ere the only to independent predictors for shorter OS plt 0.001 . Conclusions: With this large study cohort, our study suggests that survival endpoints are not different beteen omen ith stage I endometrial carcinoma ho underent lymphadenectomy compared to those ho did not. It appear that omitting lymphadenectomy for omen ith stage I disease is not associated ith any orse survival outcome after matching for stage, grade and adjuvant management.,J Clin Oncol 34, 2016 suppl; abstr e17105 ,Publication Only Gynecologic Cancer